The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436).
Mary W. F. Azer
No relevant relationships to disclose
Alexander M. Menzies
No relevant relationships to disclose
Lauren Haydu
No relevant relationships to disclose
Richard Kefford
Consultant or Advisory Role - GlaxoSmithKline
Georgina V. Long
Consultant or Advisory Role - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline